Pharmacodynamic assessment of amoxicillin-sulbactam against acinetobacter baumannii: Searching the optimal dose and infusion time through a human ex-vivo model

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 5, 2009, Pages 348-352

  Bantar, Carlos ^a   Canigia, Liliana Fernández ^b   Berger, María Alejandra ^b   Soutric, Jorge L ^c   Arenoso, Héctor ^c  

^a Laboratorio Domingo I Nanni   (Argentina)

^b HOSPITAL ALEMÁN   (Argentina)

^c Dto Médico Laboratorios Bagó S A   (Argentina)

Author keywords

Acinetobacter; Amoxicillin sulbactam

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; BETA LACTAMASE INHIBITOR; SULBACTAM; TRIFAMOX; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL COUNT; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG INFUSION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; INCUBATION TIME; INOCULATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SERUM; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; TIME;

ACINETOBACTER BAUMANNII; ADULT; AMOXICILLIN; CROSS-OVER STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SINGLE-BLIND METHOD; SULBACTAM; TIME FACTORS;

EID: 77953704214     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702009000500006     Document Type: Article

References (27)

1. Bergogne-Bérézin E. and Towner K.J. Acinetobacter spp. As nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148-65.
2. Lortholary O., Fagon J-Y., Hoi A.B., Slama M.A., et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 1995; 20:790-96.
3. Brown S., Bantar C., Young H-K., Amyes S. Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2. The Lancet 1998; 350:186-87.
4. Tognim, M.C., Andrade S.S., Silbert S., et al. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int J Infect Dis 2000; 8: 284-291.
5. Afzal-Shah M., and Livermore D.M. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 1998; 41:576-577.
6. Gales A. C., Jones R.N., Sader H.S. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006; 12:315-321.
7. Bantar C., Famiglietti A., Radice M., et al. A 7-year national survey on bacterial resistance in bronchoalveolar lavage from patients hospitalized in Argentina. Diagn Microbiol Infect Dis 2008; 60:65-9.
8. Villegas M.V., Kattan J.N., Correa A., et al. Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals. Antimicrob Agents Chemother 2007; 51:2001-4.
9. Campos Furtado G.H., Teixeira Martins S., Oliveira Machado A.M., et al. Clinical Culture Surveillance of Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter Species in a Teaching Hospital in Sao Paulo, Brazil: A 7-Year Study. Infect Control Hosp Epidemiol 2006; 27:1270-1273
10. Zavascki A.P., Soares F.C., Superti S.V., et al. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007; 30:187-189.
11. Levin A.S. and Oliveira M.S. The challenge of multidrug resistance: the treatment of Gram-negative rod infections. Shock 2008; Aug 8 [Epub ahead of print].
12. Joly-Guillou M.L., Herrman J.L., Bourdelier E., Bergongne-Bérézin E. Bactericidal in-vitro activity of b-lactams and β-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. J Antimicrob Chemother 1995; 6:619-629.
13. Bantar C., Schell C., Posse G., et al. Comparative time-kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumannii. Diagn Microbiol Infect Dis 2008;61:309-314.
14. Oliveira M.S., Prado G.V., Costa S.F., et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 2008; 61:1369-75.
15. Bantar C, Nicola F, Arenoso H et al. Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-b-lactamase inhibitor combination, against Escherichia coli. Antimicrob Agents Chemother 1999; 43:1503-4.
16. Bantar C, Nicola F, Fernandez Canigia L, et al. Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through a pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms. J Chemother 2001; 13: 402-6.
17. Bantar C, Nicola F, Arenoso H, Soutric J, Caruso N, Fernández Canigia L. An ex vivo pharmacodynamic study comparing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae. J Chemother 2004; 16:248-54.
18. Soutric J, Bantar C, Caruso N et al. Review of pharmacokinetic, pharmacodynamic and clinical studies with a modern combination of amoxicillin/sulbactam. Chemotherapy 2006; 52:200-4.
19. Betrosian A.P., Frantzeskaki F., Xanthaki A., Douzinas E.E. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Journal of Infection 2008; 56:432-436
20. Levin A.S., Levy C.E., Manrique A.E., et al. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003; 21:58-62.
21. Cisneros J.M., Reyes M.J., Pachón J., et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22:1026-32.
22. Jellison T.K., Mckinnon P.S., Rybak M.J.: Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenemcilastatin or ampicillin-sulbactam. Pharmacotherapy 2001; 21:142-48.
23. Wood G.C., Hanes S.D., Croce M.A., et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34:1425-30.
24. Lodise T.P., Lomaestro B.M., Drusano G.L. Application of Antimicrobial Pharmacodynamic Concepts into Clinical Practice: Focus on b-Lactam Antibiotics. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26:1320-32.
25. Bantar C., Schell C., Posse G., et al. Comparative time-kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2008; 61:309-14.
26. Lodise T.P. Jr, Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357-63.
27. Jones RN, Fritsche TR, Moet GJ. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation. Diagn Microbiol Infect Dis 2008; 61:76-9.